Ulcerative Colitis

Dr. Simonetto is involved in several studies using artificial intelligence.

The investigators will now move forward testing the 150 mg dosage of the treatment in a phase 3 trial.

The overall strength of association was directly related to the number of affected first-degree relatives and was modified by IBD subtype and age of diagnosis.

A group of experts discuss new and emerging therapies for IBD.

The long-term efficacy of fundoplication surgery has not previously been explored for the management of the symptoms of GERD.

Patients with inflammatory bowel disease are at an increased risk of developing depression.

The adverse event rate was 2.2% for patients with IBD following 1 dose of the vaccine.

Current smoking status, emergent/urgent surgery, and abdominoperineal resection were considered risk factors for total complications.

In data presented at AAD, investigators found increased odds of GERD in patients with rosacea compared to a control group without rosacea.

There was an adequate response for pediatric patients on biologics to the H1N1 and H3N2 serotypes.

Using a main adjusted model, the investigators found an increase of 31.8 percentage points in test completion in the intervention group compared to the control group.

The relative risk of hospitalization was substantially lower for patients with IBD and COVID-19 who were treated with biologics (compared to patients not treated with biologics.

The advent of biologics has transformed care for patients with inflammatory bowel disease.

There is a need to study more combination therapies for the treatment of inflammatory bowel disease.

Investigators found 31% of patients treated with aldafermin 0.3 mg had an improvement in liver fibrosis of at least 1 stage with no worsening of NASH.

Investigators found that a starch- and sucrose-reduced diet (SSRD) increased the intake of several micronutrients which correlated weakly with symptom improvement.

For patients treated with DOACs, the investigators suggest temporarily interrupting treatment rather than continued use.

Upadacitinib is now approved for ulcerative colitis, atopic dermatitis, and psoriatic arthritis.

The decision represents the first ever upadacitinib for a gastroenterological disease.

Approximately 60% of patients with ulcerative colitis treated with guselkumab achieved clinical remission.

There was a 2.4-fold increase in cancer among patients with pediatric-onset inflammatory bowel disease.

Assessing fat free mass and reduced intake are particularly important in identifying malnutrition in patients with inflammatory bowel disease.

In data presented at ECCO 2022, investigators identified the optimal infliximab cut-off level was 4 μg/ml.

AHN is one of the few hospitals who have implemented this type of program to treat IBD complications.

There is no clinically meaningful differences in safety and efficacy between biologics and biosimilars.

Guselkumab is being studied as a treatment for both Crohn's disease and ulcerative colitis.

The data presented during ECCO 2022 involved IBD patients both in Hong Kong and the US.

There is concerns over missed early screenings for gastrointestinal cancers due to the COVID-19 pandemic.

The efficacy rates at weeks 12 and 52 were numerically lower in ileal only Crohn’s disease relative to colonic only and ileal-colonic.

A higher proportion of patients treated with mirikizumab achieved clinical remission at week 12 compared to placebo.